Evidence map›Paper›PMID 42437657›Full record

ArticlePharmaceutical statistics

The Impact of Model Misspecification on the Individual Causal Association in Surrogate Endpoint Evaluation.

Gokce Deliorman, Florian Stijven, Wim Van der Elst, Maria Del Carmen Pardo, Ariel Alonso

Abstract read
In one paragraph

Article in Pharmaceutical statistics. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Gokce DeliormanDepartment of Statistics and O.R, Complutense University of Madrid, Madrid, Spain.ORCID 0000-0002-3110-5070
Florian StijvenL-BioStat, KU Leuven, Leuven, Belgium.ORCID 0000-0002-4574-8261
Wim Van der ElstJanssen Pharmaceutica, Companies of Johnson & Johnson, Beerse, Belgium.ORCID 0000-0003-4315-7406
Maria Del Carmen PardoDepartment of Statistics and O.R, Complutense University of Madrid, Madrid, Spain.ORCID 0000-0002-4623-6321
Ariel AlonsoL-BioStat, KU Leuven, Leuven, Belgium.ORCID 0000-0003-4966-1689

Funding

Agentschap Innoveren en OndernemenJohnson & Johnson Innovative Medicine HBC.2022.0145MCIN/AEI/10.13039/501100011033/ and ERDF Away of Making Europe PID2022-137050NB-I00
6 · The paper itself

Abstract

Surrogate endpoints are often used in place of expensive, delayed, or rare clinical endpoints in clinical trials. However, regulatory authorities require thorough evaluation to accept these surrogate endpoints as reliable substitutes. One evaluation approach is the information-theoretic causal inference framework, which quantifies surrogacy using the individual causal association (ICA). Like most causal inference methods, this approach relies on models that are only partially identifiable. For continuous outcomes, a normal model is often used. In this study, we explored the effects of model misspecification across various scenarios. We first considered true data-generating mechanisms based on multivariate

Indexed as

BiomarkersClinical Trials as TopicEndpoint DeterminationModels, StatisticalComputer SimulationHumansSchizophreniaBiomarkersD‐vine copulaindividual causal association (ICA)model misspecificationnonnormalitysurrogate endpoint

Identifiers

PMID42437657
PMCPMC13356973

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.